文献速递肝病

Agile 3+与Agile 4评分预测代谢功能障碍相关脂肪性肝病患者的慢性肾脏病发生

Agile 3+ and Agile 4 scores predict chronic kidney disease development in metabolic dysfunction-associated steatotic liver disease.
PubMed 文献 · Aliment Pharmacol Ther · 2024-08-14

在3240例无慢性肾脏病的代谢功能障碍相关脂肪性肝病患者中,基于瞬时弹性成像的Agile评分评估的进展性肝纤维化与慢性肾脏病发生风险升高相关,且Agile评分对肾脏结局的预测优于瞬时弹性成像测定的肝硬度。

要点

  • 中位随访3.6年,187例(5.8%)发生慢性肾脏病。
  • Agile 3+高风险组(>0.68)慢性肾脏病发生风险较低风险组(<0.45)高2.77倍(95%CI 1.89-4.07;p<0.001)。
  • Agile评分对肾脏结局的预测优于瞬时弹性成像测定的肝硬度。

核心结论

  • 在无慢性肾脏病的代谢功能障碍相关脂肪性肝病患者中,Agile评分评估的进展性肝纤维化与慢性肾脏病发生风险升高显著相关。

研究设计与样本

  • 研究纳入2006年7月至2018年10月期间接受瞬时弹性成像的3240例代谢功能障碍相关脂肪性肝病且无慢性肾脏病的参与者。

主要发现

  • 中位随访3.6年,187例参与者(5.8%)发生慢性肾脏病。
  • 按Agile 3+评分三分组,多变量Cox模型显示高风险组(Agile 3+ >0.68)较低风险组(Agile 3+ <0.45)慢性肾脏病发生风险高2.77倍(95%CI 1.89-4.07;p<0.001)。
  • 中位随访3.4年,高风险组较低风险组发生次要结局(两次连续测量eGFR下降25%)的风险高2.41倍(95%CI 1.86-3.12;p<0.001)。
  • Agile 4评分观察到类似结果。
  • 预测检验显示Agile评分对肾脏结局的预测优于瞬时弹性成像测定的肝硬度。

关键数值与推荐

  • 慢性肾脏病定义:连续两次测量估算肾小球滤过率(eGFR)<60 mL/min/1.73 m2或蛋白尿(试纸≥1+)。
  • 次要结局:连续两次测量eGFR下降25%。
  • Agile 3+高风险组阈值>0.68,低风险组阈值<0.45。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Despite the development of transient elastography (TE)-based Agile scores for diagnosing fibrotic burden in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), their applicability in predicting kidney outcomes remains unclear. We aimed to investigate the association between liver fibrotic burden, as assessed by Agile scores, and the risk of incident chronic kidney disease (CKD) in patients with MASLD. METHODS: A total of 3240 participants with MASLD but without pre-existing CKD who underwent TE between July 2006 and October 2018 were selected. The primary outcome was incident CKD, defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 or proteinuria (≥1+ on dipstick) on two consecutive measurements. The secondary outcome was a 25% decline in eGFR measured on two consecutive visits. RESULTS: During a median follow-up of 3.6 years, 187 participants (5.8%) developed incident CKD. When stratified into three groups according to Agile 3+ scores, multivariable Cox models revealed that risk of incident CKD was 2.77-fold (95% confidence interval [CI], 1.89-4.07; p < 0.001) higher in the high-risk group (Agile 3+ >0.68), compared to the low-risk group (Agile 3+ <0.45). During a median follow-up of 3.4 years, the high-risk group had a 2.41-fold higher risk (95% CI, 1.86-3.12; p < 0.001) of experiencing the secondary outcome, compared to the low-risk group. Similar findings were observed for Agile 4 scores. Prediction testing revealed that Agile scores were better predictors of kidney outcomes, compared to liver stiffness measured by TE. CONCLUSIONS: In patients with MASLD, but without CKD, advanced liver fibrosis measured by Agile scores was significantly associated with a higher risk of incident CKD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Jung CY, Lee JI, Ahn SH, et al. Agile 3+ and Agile 4 scores predict chronic kidney disease development in metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther. 2024. PMID: 39139053. doi:10.1111/apt.18213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。